Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes
Figure 7
Fc-FGF21(RG) exhibited improved pharmacokinetics in mice and cynomolgus monkeys.
(A) Plasma concentrations vs. time profile of Fc-FGF21(RG) following iv (closed triangular) or sc (opened square) administration at 20 mg/kg in male C57BL6 mice. (B) Plasma concentrations vs. time profile of native FGF21 (closed circle), Fc-FGF21 (opened circle) or Fc-FGF21(RG) (closed triangular) following iv administration in male cynomolgus monkeys. FGF21: 10 mg/kg; both Fc compounds: 23.5 mg/kg.